

Roll Back Malaria
Affordable Medicines Facility - malaria
Monitoring and Evaluation (M&E) Workshop
10 -11 June 2009, Dar es Salaam, Tanzania
Objectives, Background and Agenda

Contents

1. Workshop objectives
2. Background
3. Draft agenda

Contact information:

- RBM Secretariat focal point: **Dr Jan Van Erps** (email: vanerpsj@who.int)
- Events Organizer in Tanzania for logistics, travel and accommodation financed by the Global Fund: **Compass Communications Ltd** (email & internet: info@compass-tz.com / www.compass-tz.com, Telephone & Fax: +255-22-218 25 96 / 218 24 05)

1) Workshop Objectives

Roll Back Malaria (RBM), through its Harmonization Working Group (HWG) and the Monitoring and Evaluation Reference Group (MERG), is co-convening with the Global Fund an AMFm Monitoring & Evaluation (M&E) workshop for countries on 10th-11th June 2009 in Tanzania. The objectives of the workshop are to:

1. Inform potential AMFm Phase 1 countries about the content of the M&E Technical Framework, including country roles and responsibilities;
2. Receive country feedback on the proposed M&E Technical Framework, with emphasis on its relevance, quality, feasibility and aspects that may need improvement; and
3. Provide technical partners an opportunity to know, in more detail, those aspects of country implementation that will need their support, during planning and implementation of AMFm Phase 1.

2) Background***Introduction to the AMFm***

The AMFm is a financing mechanism designed to expand access to affordable artemisinin-based combination therapy (ACTs) for malaria. It aims to enable countries to increase the provision of affordable ACTs through the public, private and NGO sectors. Thereby, saving lives and reducing the use of less effective malaria treatments, such as CQ and SP. By increasing access to ACTs and displacing artemisinin monotherapies from the market, the AMFm also seeks to delay resistance to the relatively new drug, artemisinin. In order to achieve this, the AMFm will negotiate a lower manufacturer sales price for ACTs which is available to all wholesale buyers (i.e. public, non-government, and private for profit) at the country level; and then pay a significant proportion of this price on behalf of buyers (a buyer

“co-payment”). For patients who pay for treatment, this is expected to result in a reduction in the price of ACTs from about US\$6-10 per treatment to about US\$0.20-0.50 per treatment.

The AMFm was developed by a broad coalition of stakeholders in the Roll Back Malaria Partnership, and will be hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund). At its 18th meeting the Global Fund Board approved the Policy Framework and Implementation Plan set out in the AMFm Ad Hoc Committee Report to the Board (GF/B18/7 – the “AMFm Report”), and reaffirmed its decision to host and manage the AMFm for an initial phase (“Phase 1”) in a limited number of countries. For further details refer to: <http://www.theglobalfund.org/en/amfm/?lang=en>

As per the Global Fund Board decision, AMFm Phase 1 will be independently evaluated. The results of this evaluation will assist the Board’s future decision to expand, modify or terminate AMFm, as a line of business with the Global Fund.

The Monitoring and Evaluation (M&E) Technical Framework: an Overview

The Monitoring and Evaluation (M&E) Technical Framework¹, sets out the approach to monitoring, operational research and independent evaluation for AMFm Phase 1. It defines sought outputs and outcomes from the *combined effects* of the two main components of AMFm Phase 1: (i) manufacturer negotiations and buyer co-payments and; (ii) supporting interventions.

Main components of the AMFm Phase 1 Technical Framework include, monitoring, operational research and an independent evaluation, with the following objectives:

- **In-country monitoring of supporting interventions²:** To keep track of implementation progress on supporting interventions, identify problems that require the attention of managers, and inform subsequent decisions and action.
- **Operational Research (OR):** To enable learning by doing, and alleviate constraints on implementation via studies whose findings will be applicable to the local context. The emphasis is on applied knowledge, in a particular country context. Additionally, OR involving multiple countries will be undertaken to examine cross cutting issues for AMFm. Countries are responsible for the conduct or commissioning of county specific operational research (OR). The Global Fund Secretariat will contract out multi-country OR leading research and academic institutions, to be selected by competitive tender.
- **Independent Evaluation:** To determine whether, and to what extent, AMFm Phase 1 achieves its objectives. This is the principal deliverable to be considered by the Board in 2011. Data analysis for the Independent Evaluation will be undertaken by an independent contractor to be selected by competitive tender.

More specifically, the M&E Technical Framework lists evaluation questions, details design, methods, indicators to be used for the evaluation, potential ‘red flags’ (i.e. serious failures),

¹ The draft M&E Technical Framework is attached to the workshop invitation, together with this agenda

² As defined in the Global Fund to Fight AIDS, Tuberculosis and Malaria. Report of the Affordable Medicines Facility – Malaria Ad Hoc Committee, Eighteenth Board Meeting:
http://www.theglobalfund.org/documents/board/18/GF-B18-07_ReportAMFmAdHocCommittee.pdf

and the responsibilities of respective parties for the independent evaluation. Additionally, guidance about performance measures and issues of design and implementation for other components of the Framework, that either support, or inform the evaluation of AMFm are also included.

It is envisaged that the M&E Technical Framework document will be used by a range of stakeholders. Principal amongst these are participating countries, but also technical and development partners, contractors, and the broader international health community. Additionally, it may be of interest to policy makers whose malaria-endemic countries are not included in Phase 1 of AMFm, but stand to benefit from a potential global roll-out after Phase 1. Finally, the Global Fund Secretariat will also find it a useful reference.

Draft

3) **Draft Agenda***Agenda 10 June 2009*

TIME	ACTIVITY	SPEAKER & RAPPORTEUR(S)
8.15 - 9.00	Registration	
Morning Session 1		
9.00	Welcome & Setting the Scene	HWG
9.15	<ul style="list-style-type: none"> AMFm: Recap of Objectives & Key Facts Questions & Answers 	CHAI
9.45	Overview of M&E Technical Framework (Part 1) <ul style="list-style-type: none"> Purpose & Structure of the Framework What is Being Measured? How is it Being Measured? Questions & Answers 	Global Fund
11.00	Tea/Coffee	
Morning Session 2		
11.20	Overview of M&E Technical Framework	Global Fund
	Overview of M&E Technical Framework (Part 2) <ul style="list-style-type: none"> Who is Doing What? M&E Oversight Arrangements Red Flags (i.e. defining serious problems) Key Milestones & Events Questions & Answers 	Global Fund
13.00	Lunch	
Afternoon Session 1		
14.00	Country Monitoring: Some Specifics <ul style="list-style-type: none"> Monitoring supporting interventions & Performance Framework Requirements Monitoring of Private Sector: What is Expected of Countries? How similar are monitoring requirements for AMFm compared to routine GF country grants? Questions & Answers 	Global Fund
14.30	Pharmacovigilance: implementation and monitoring	WHO
15.15	Operational Research: Structure, Themes & Process Funding Sources	Global Fund & CHAI
15.45	Tea/Coffee	
Afternoon Session 2		
16.00	Buzz Groups: Country Views on M&E Framework	Group Facilitation: HWG, MERG, CHAI and GF
17.30	Feedback from Groups & Summing Up	MERG
18.15	Close	
18.30 (half hour)	Facilitators' Meeting	HWG, MERG, CHAI and GF

Agenda 11 June 2009

TIME	ACTIVITY	SPEAKER & RAPPORTEUR(S)
Morning Session 1		
8.30	AMFm Country Application Form <ul style="list-style-type: none"> • Overview • M&E and OR Sections • Questions & Discussion 	Global Fund
9.30	Benefit of Experience & Hindsight: M&E Lessons From ACT market Studies <ul style="list-style-type: none"> • ACTwatch • MMV • HAI 	ACTwatch MMV HAI MERG
10:30	Questions & Discussion about ACT market studies	ACTwatch MMV HAI MERG
11.00	Tea/Coffee	
Morning Session 2		
11.15	Country Groups <ul style="list-style-type: none"> • Review of countries draft proposals (M&E section) • Identification of possible M&E challenges • Identification of management response • Identification of M&E Technical Assistance Needs 	Group Facilitation: HWG, CHAI and MERG
13.00	Lunch	
Afternoon Session 1		
14.00	Country groups, continues	
16:00	Plenary: Feedback from Groups, Summing Up & Next Steps	HWG, MERG, CHAI and GF
17:00	Official Close	